CSIG-17. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA MODELS TO TRAMETINIB TREATMENT

INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor. With limited effective therapeutic strategies, prognosis for GBM is very poor. Our previous study shows that the expression of Protein Arginine Methyltransferase 5 (PRMT5) is upregulated in GBM; its inhibition promote...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Otani, Yoshihiro, Namagiri, Sriya, Thammegowda, Shilpa, Sur, Hannah, Chowdhury, Ashis, Lewis, Cole, Shimizu, Toshihiko, Lee, Tae Jin, Maric, Dragan, Yoo, Ji Young, Heiss, John, Kaur, Balveen, Banasavadi-Siddegowda, Yeshavanth Kumar
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Cell Signaling and Signaling Pathways
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650434/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.129
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items